KRYS.US Krystal Biotech Inc

Healthcare Biotechnology USA Stocks
305.23 USD
Close of Nov 15, 2026
202.99 382.54
Market cap
USD 9.05B
P/E
41.5x
P/B
6.30x
ROE
16.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KRYS.US undervalued?

Graham number

The Graham number of Krystal Biotech Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Krystal Biotech Inc fundamental analysis

No fundamental analysis for Krystal Biotech Inc yet.

Krystal Biotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in…

Full company profile